Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Similar VTE rates seen with tofacitinib, TNF inhibitors
Desai RJ et al. Arthritis Rheumatol. 2018;70(suppl 10), Abstract L09
Key clinical point: Rheumatoid arthritis patients treated with tofacitinib showed no excess incidence of venous thromboembolism, compared with patients on a tumor necrosis factor inhibitor.
Major finding: Propensity score–adjusted rates of VTE were 33% higher with tofacitinib, compared with TNF inhibition, which was not a statistically significant difference.
Study details: Review of 51,160 rheumatoid arthritis patients from U.S. health insurance databases.
Disclosures: Dr. Kim has received research support from Bristol-Myers Squibb, Pfizer, and Roche.
Citation:
Desai RJ et al. Arthritis Rheumatol. 2018;70(suppl 10), Abstract L09